


# EZSolution™ LDN193189

08/20

**ALTERNATE NAMES:** 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline; DM-3189

**CATALOG #:** B3074-5 5 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>25</sub>H<sub>22</sub>N<sub>6</sub>

**MOLECULAR WEIGHT:** 406.5

**CAS NUMBER:** 1062368-24-4

**APPEARANCE:** Liquid

**PURITY:** ≥98%

**SOLUBILITY:** DMSO (10 mM)

**DESCRIPTION:** EZSolution™ LDN193189 is a 10.9 mM (5 mg in 1.13 ml) solution of LDN193189 (Cat. No. B3067) in anhydrous DMSO.

**STORAGE TEMPERATURE:** -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCES:**

1. Yu, P.B., Deng, D.Y., Lai, C.S., et al. BMP type I receptor inhibition reduces heterotopic ossification. *Nature Medicine* 14(12), 1363-1369 (2008).
2. Lee, Y.C., Cheng, C.J., Bilén, M.A., et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. *Cancer Research* 71(15), 5194-5203 (2011).
3. Boergemann, J.H., Kopf J., Yu, P.B., et al. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. *Int J Biochem Cell Biol.* 42(11): 1802–1807 (2010).

**RELATED PRODUCTS:**

LDN-212854 (Cat. No. B2641)  
 LDN-193189 dihydrochloride (Cat. No. B2986)  
 EZSolution™ LDN193189 HCl (Cat. No. 2092)  
 LDN-193189 (Cat. No. B3067)  
 LDN193189 HCl (Cat. No. 1995)

**DISCLAIMER:** *FOR RESEARCH USE ONLY! Not to be used on humans.*